AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease

Mankind unveils HealthOK’s 100% vegetarian multivitamin tablets campaign with Archana Puran Singh

Naturo & Orgo empowering brands through excellence

The company offers customized formulations tailored to align with each brand’s identity and consumer needs

Knya forays into medical equipment category with '6sense Stethoscope'

The stethoscope features high acoustic sensitivity and active noise cancellation, minimizing ambient interference to improve auscultation clarity, particularly in noisy hospital settings

Amcor's Bloom Biorenewables secures $14 million Series A Funding

Bloom has pioneered a technology to transform plant waste into valuable chemical products

Emcutix and WiQo sign licensing partnership for derma-cosmetic treatments in India

PRX-PLUS has a unique product feature with its deep-impacting formula

Lonza implements streamlined operating model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy

Curium completes acquisition of Monrol

Positions Curium as leading manufacturer of Lu-177 isotope

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)